Mesoblast Ltd (MESO) stock
Close on Nov 11, 2026Market cap $1.77BP/E –Yield –
Mesoblast Ltd grew revenue 599.2% to $120.25M over fiscal 2026. Free cash flow was -$44.66M. At the latest close the market valued the company at $1.77B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Jun 30, 2026
Valuation
- Market cap
- $1.77B
- P/E ratio
- –
- Price to sales
- 14.72
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -2.52%
Fundamentals
- Revenue
- $120.25M
- Net income
- -$57.50M
- EPS, diluted
- -$0.04
- Free cash flow
- -$44.66M
Trading
- Previous close
- $13.99
- Open
- $13.91
- Day's range
- $13.64 – $14.20
- Volume
- 208,386
- Average volume (20 days)
- 299,062
- Beta (5 years)
- 1.51
- 52-week range
- $11.89 – $21.50
- RSI (14 days)
- 46.3
- Volatility (1 year)
- 57.2%
- Relative volume
- 0.84×
- WACC
- 12.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MESO | S&P 500 | Difference | MESO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -4.5% | -2.4% | −2.1 pts | ||
| 3 months | -19.3% | -1.2% | −18.2 pts | ||
| Year to date | -24.3% | +12.3% | −36.6 pts | ||
| 1 year | -12.1% | +12.4% | −24.6 pts | ||
| 3 years | +454.9% | +78.8% | +376.1 pts | +77.0% | +21.4% |
| 5 years | +12.4% | +75.2% | −62.7 pts | +2.4% | +11.9% |
| 10 years | +46.8% | +311.1% | −264.3 pts | +3.9% | +15.2% |
Twelve years at a glance
Fiscal years 2015 to 2026, USD
Revenue
Gross profit
Net income
EPS, diluted
Free cash flow
Press releases
Releases Mesoblast filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Mesoblast
Biological Products, (No Diagnostic Substances)
Mesoblast Limited is a commercial-stage biotechnology company focused on developing and commercializing allogeneic cellular medicines. The company utilizes proprietary technology based on mesenchymal lineage adult stem cells to discover and manufacture therapeutic products that promote tissue repair and modulate immune responses. Its commercial product is Ryoncil (remestemcel-L-rknd), which is approved in the United States for treating steroid-refractory acute graft-versus-host disease in pediatric patients. In addition, Mesoblast is advancing clinical pipeline candidates including rexlemestrocel-L for degenerative disc disease and cardiovascular conditions. The company primarily serves healthcare providers, clinical transplant centers, and patients with serious inflammatory and cardiovascular conditions.
Company profile, executives and historyMesoblast stock: common questions
What is Mesoblast's stock price?
MESO closed at $13.65 on Nov 11, 2026, down 2.43% on the day. Over the past 52 weeks it traded between $11.89 and $21.50.
What is Mesoblast's market cap?
Mesoblast was worth $1.77B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MESO's P/E ratio?
Mesoblast lost money over fiscal 2026 (diluted EPS -$0.04), so it has no meaningful P/E ratio.
How much revenue does Mesoblast make?
Mesoblast reported revenue of $120.25M for fiscal 2026, up 599.2% from a year earlier.
Does Mesoblast pay a dividend?
No. Mesoblast has not paid a cash dividend over the last twelve months.
How has MESO stock performed over the past year?
Including dividends, MESO returned -12.1% over the past year, against +12.4% for the S&P 500.
Who are Mesoblast's competitors?
Companies most similar to Mesoblast by business, industry and size include IPSC, AUTL, AGEN, KYMR, RGNX.
See a number that looks wrong?